In this study, we aim to broaden our validation of EphA2 as a therapeutic target across the bone sarcoma family, particularly in osteoblastic osteosarcoma, Ewing’s sarcoma and conventional chondrosarcoma, and at establishing bone sarcoma models, tailored according to patients’ tumor characteristics. Here, EPHA2 is linked to chondrosarcoma.